Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Epinephrine Autoinjectors

Deploying Epinephrine Autoinjectors to Support Community-based COVID-19 Vaccination Campaigns

The SNS is coordinating with other federal agencies to meet ongoing state, local, tribal, and territorial preparedness and response needs and ensure resources are available to support community-based COVID-19 vaccination campaigns.

At the direction of the Assistant Secretary for Preparedness and Response (ASPR), the SNS recently procured a limited quantity of epinephrine in pre-filled autoinjectors to make available to public health jurisdictions/authorities to protect vulnerable populations with adverse reactions during their COVID-19 vaccination campaigns. This acquisition was an effort to ensure vaccination clinics in non-hospital settings would be prepared to treat potential allergic reactions, including anaphylaxis.

In February 2021, the SNS allocated 100,000 autoinjectors to all 50 states, the four largest metropolitan areas and eight territories and island jurisdictions based on their populations (pro-rata allocation). In coordination with ASPR regional emergency coordinators, each jurisdiction was engaged and offered the option to receive any amount up to their total allocation.

As of [March 23, 2021], the SNS has deployed more than 100,000 Epinephrine Autoinjectors to 62 jurisdictions that have requested them.

Related Resources

  • This page last reviewed: August 12, 2021